Embla Medical发布237MQ3销售额, 增加11%, Embla Medical posted $237M Q3 sales, up 11%, driven by new prosthetics and orthotics, with strong profits and cash flow.

Embla Medical公司报告说,2025年Q3销售额为2.37亿美元,增长11%,有机增长7%,其驱动力来自Navii和OdyssseyiQ等新产品的假肢和神经矫形术的强劲增长。 Embla Medical reported Q3 2025 sales of $237 million, up 11% reported and 7% organically, driven by strong growth in prosthetics and neuro orthotics from new products like Navii and Odyssey® iQ. 美洲的绩效在缓慢开始后有所改善,而优收销售是平坦的,病人护理略有增加。 The Americas saw improved performance after a slow start, while bracing sales were flat and patient care grew modestly. 该公司完成了对德国整形供应商Streifender的大多数投资,扩大了产品范围,实现了22%的EBITDA比值,比一年前的20%有所增加。 The company completed a majority investment in German orthopedic supplier Streifeneder, expanded its product range, and achieved a 22% EBITDA margin, up from 20% a year ago. 净利润增长17%,达到2 600万美元,自由现金流量达到3 800万美元,公司保持2.5倍的杠杆比率,同时继续执行股票回购方案。 Net profit rose 17% to $26 million, free cash flow reached $38 million, and the company maintained a leverage ratio of 2.5x while continuing its share buyback program. 全年指导未变。 Full-year guidance remains unchanged.